Treatment with Axatilimab in Chronic GVHD: How it Works and Insights into Treatment Efficacy
Panelists discuss how axatilimab, a novel therapy for chronic graft-versus-host disease (cGVHD), functions through a unique mechanism of action compared to other treatments, highlighting its potential role in cGVHD management and presenting key findings from the AGAVE-201 trial that demonstrate its efficacy and safety profile.
Video content above is prompted by the following:
Can you tell us about axatilimab and its potential role in cGVHD treatment? How does its mechanism of action differ from other therapies? Please briefly highlight the AGAVE-201 trial and data.
BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
August 11th 2024The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.
